



NAVANA PHARMACEUTICALS LIMITED

Corporate Office: House # 99, Road #04,
Block # B, Banani, Dhaka-1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals Limited and stakeholders that the Board of Directors of the company in its 18th meeting held on 13th November, 2022 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the first quarter (Q1) period ended on September 30, 2022 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the first quarter (Q1, FY-2022-2023) period ended on September 30, 2022

Sl. No	Particulars	01.07.2022-30.09.2022	01.07.2021-30.09.2021
i	Earnings Per Share (EPS)	0.91	0.76
ii	Net Operating Cash Flow Per Share (NOCFPS)	1.18	0.76
		As at 30.09.2022	As at 30.06.2022
iii	Net Asset Value (NAV)	3,763,536,646	3,483,049,323
iv	Net Asset Value Per Share	46.91	43.41

Notes:

● **Reasons of significant deviation in earning per share (EPS) and Net Operating Cash Flows Per share (NOCFPS) between the quarterly periods :-**

- ★ EPS: Increase in Sales Revenue and efficient usages of material resulted in increased gross profit for the reporting period. The reduced corporate tax rate for the period resulted in the increment of Earnings Per Share as well.
- ★ NOCFPS: The growth in our business volume and efficient utilization of working capital supported by higher receipt from other income resulted in increased Net Operating Cash Flows Per share

- In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the first quarter (Q1) period ended on September 30, 2022 in two widely circulated daily newspapers (one in Bengali and otherone in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

By order of the Board
sd/-

Dated: November 13, 2022

Joynul Abedin ACS
Company Secretary